Meeting an Unmet Need in the Nonmetastatic Castration Resistant Prostate Cancer Patient Population - Maha Hussain

(Length of Discussion: 22 min) Alicia Morgans and Maha Hussain discuss the Evaluating the Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER) phase III randomized double-blind controlled trial , in the nonmetastatic castration-resistant prostate cancer (nmCRPC) patient population which was first presented at the 2018 ASCO GU meeti...

Changing the Landscape of nmCRPC - The SPARTAN Trial - Eric Small

(Length of Discussion: 25 min) Professor Eric Small, MD talks with Dr. Neal Shore in a post ASCO GU interview on Dr. Eric Small’s plenary presentation on the phase three global SPARTAN trial. A landscape changing treatment for patients with non-metastatic castration resistant prostate cancer. The first drug approved by FDA to satisfy an unmet need for nmCRPC or m0 patients. Dr. Eric Small gives an...

Discussion on PROSPER: Safety and Efficacy Study of Enzalutamide in Patients with nmCRPC - Thomas Keane

(Length of Discussion: 7 min) Dr. Thomas Keane reviews the first presentation on the PROSPER study which was a much awaited presentation presented by Dr. Maha Hussain at the recent 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium . Dr. Hussain started her presentation on PROSPER, a phase III randomized double-blind controlled trial, Safety and Efficacy Study of...